2. Academic Validation
  3. Fibroblast growth factor 2 (FGF2) ameliorates the coagulation abnormalities in sepsis

Fibroblast growth factor 2 (FGF2) ameliorates the coagulation abnormalities in sepsis

  • Toxicol Appl Pharmacol. 2023 Feb 1;460:116364. doi: 10.1016/j.taap.2023.116364.
Yuanyuan Sun 1,  Fanrong Ye 1,  Ding Li 1,  Hongjing Yang 1,  Tingting Xu 1,  Xincun Zhong 1,  Yilun Lu 1,  Hongmin Zhou 1,  Jingye Pan 2
Affiliations

Affiliations

  • 1 Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province, Wenzhou, China; Wenzhou Key Laboratory of Critical Care and Artificial Intelligence, Wenzhou, China.
  • 2 Department of Intensive Care Unit, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province, Wenzhou, China; Wenzhou Key Laboratory of Critical Care and Artificial Intelligence, Wenzhou, China; Collaborative Innovation Center for Intelligence Medical Education, Wenzhou, China; Zhejiang Engineering Research Center for Hospital Emergency and Process Digitization, Wenzhou, China. Electronic address: wmupanjingye@126.com.
PMID: 36621722 DOI: 10.1016/j.taap.2023.116364
Abstract

Background: Sepsis is defined as a life-threatening organ dysfunction caused by dysregulation of the host response to Infection. There is still a lack of specific treatment for sepsis. Here, we report that Fibroblast growth factor-2 (FGF2) can reduce the mortality of sepsis by ameliorating the coagulation abnormalities.

Methods: FGF2 was intraperitoneally injected into septic mice induced by lipopolysaccharide (LPS) and then assessed for coagulation response, organ damage and survival. RAW264.7 cells with or without FGF2 pretreating were exposed to LPS, and then changes in coagulation related factors expression and signaling were tested.

Results: The findings showed that intraperitoneal injection of FGF2 inhibited coagulation activity, reduced lung and liver damage, and increased survival in septic mice. In RAW264.7 cells, LPS upregulated the expression of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1); however, pretreatment with FGF2 prevented this upregulation, while FGF2 knockdown exacerbated TF upregulation. Moreover, FGF2 suppressing the Akt/mTOR/S6K1 signaling pathway in septic mice and RAW264.7 cells stimulated by LPS.

Conclusions: This study revealed a therapeutic role of FGF2 in ameliorating the coagulation abnormalities during sepsis.

Keywords

Coagulation; DIC; FGF2; PAI-1; Sepsis; TF.

Figures
Products